C4 Therapeutics, Inc. (CCCC)

Market Cap	285.89M
Revenue (ttm)	33.67M
Net Income (ttm)	-105.50M
Shares Out	70.59M
EPS (ttm)	-1.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,298,083
Open	4.200
Previous Close	4.150
Day's Range	3.840 - 4.200
52-Week Range	1.060 - 11.880
Beta	3.06
Analysts	Buy
Price Target	10.00 (+146.91%)
Earnings Date	Oct 31, 2024

About CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CF...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 2, 2020
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: CCCC
• Website: https://www.c4therapeutics.com

Financial Performance

In 2023, C4 Therapeutics's revenue was $20.76 million, a decrease of -33.25% compared to the previous year's $31.10 million. Losses were -$132.49 million, 3.37% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for CCCC stock is "Buy." The 12-month stock price forecast is $10.0, which is an increase of 146.91% from the latest price.

Price Target

$10.0

(146.91% upside)

Analyst Consensus: Buy